WOODRIDGE, Ill., Oct. 5 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. , a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and inflammation, will present two abstracts at the Infectious Diseases Society of America (IDSA) 44th Annual Meeting. IDSA's annual meeting brings together more than 4,500 infectious disease and HIV/AIDS physicians, researchers and other specialists. This year's meeting will take place in Toronto, Ontario, Canada from October 12 - October 15, 2006.
(Logo: http://www.newscom.com/cgi-bin/prnh/20050428/CGTH039LOGO )
The Company's poster presentations report, for the first time, data regarding the clinical safety and efficacy of cethromycin against acute bacterial sinusitis.
Poster Presentation Schedule Friday, October 13, 2006, 12:30 pm Eastern Daylight Time -- A Phase 2 Comparative Study of the Safety & Efficacy of Three Oral Doses of Cethromycin for the Treatment of Acute Bacterial Sinusitis (ABS) -- A Phase 2/3 Comparative Study of the Safety & Efficacy of Cethromycin 150 mg QD vs. Cethromycin 150 mg BID for the Treatment of Acute Bacterial Sinusitis (ABS) About Advanced Life Sciences
Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and inflammation. The Company's lead candidate, cethromycin, is a novel ketolide antibiotic in late-stage clinical development for the treatment of respiratory tract infections.
Forward-Looking Statements
Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. These risks and uncertainties include, among others, those relating to technology and product development, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in Advanced Life Sciences' filings with the Securities and Exchange Commission. Advanced Life Sciences undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.
Photo: http://www.newscom.com/cgi-bin/prnh/20050428/CGTH039LOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comAdvanced Life Sciences Holdings, Inc.CONTACT: Investor Relations, Edward P. Flavin of Advanced Life SciencesHoldings, Inc., +1-630-739-6744 Ext. 211
Web site: http://www.advancedlifesciences.com/
